Edition:
United Kingdom

People: Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

229.89USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$229.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
721,151
52-wk High
$388.67
52-wk Low
$216.13

Papadopoulos, Stelios 

Dr. Stelios Papadopoulos, Ph.D. is the Independent Chairman of the Board of Biogen Inc. Dr. Papadopoulos has served as one of our directors since 2008 and as our independent Chairman since June 2014. Dr. Papadopoulos also serves as the Chairman of Regulus Therapeutics Inc., a biopharmaceutical company, and Exelixis, Inc., a drug discovery and development company that he co-founded in 1994. Previously, he was an investment banker with Cowen & Co., LLC, a financial services company, focusing on the biotechnology and pharmaceutical sectors, from 2000 until his retirement as Vice Chairman in August 2006. Prior to joining Cowen & Co., Dr. Papadopoulos served for 13 years as an investment banker at PaineWebber, Inc., a financial services company, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Dr. Papadopoulos is also a director of BG Medicine, Inc., a diagnostics company focused on the development and commercialization of cardiovascular diagnostic tests. Having founded multiple life sciences companies and worked as an investment banker focused on the life sciences industry, Dr. Papadopoulos brings to our Board of Directors a firsthand understanding of the demands of establishing, growing and running life sciences businesses.

Basic Compensation

Total Annual Compensation, USD 200,500
Restricted Stock Award, USD 444,448
Long-Term Incentive Plans, USD --
All Other, USD 24,500
Fiscal Year Total, USD 669,448

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --